Journal article · 2026 · Open access
Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions
Cell and Gene Therapy Insights, 12(3), 265–272 · Published 28 April 2026 · DOI 10.18609/cgti.2026.034
In brief
“Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions” is a 2026 journal article by Mathias Kroll and Kilian Kelly, published in Cell and Gene Therapy Insights. OpenAlex counts 0 citations as of 21 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Cell and Gene Therapy Insights.
- Citations
- 0
- Authors
- 2
Abstract
Induced pluripotent stem cell (iPSC) technology has opened new opportunities to develop novel therapies consisting of cells of almost any type such as neurons, cardiomyocytes, beta islet cells, T or NK cells, mesenchymal stromal cells, and many others. These have the potential to slow or halt the progression of a broad range of degenerative diseases or even restore lost organ function. Over the last 10 years, these therapies have progressed into clinical efficacy trials, and the first major products are approaching market approval. As the global Industry pipeline continues to expand and mature, the need for efficient scaling, high output, and acceptable cost of goods requires new technical solutions. Every stage in the manufacture of an iPSC-derived cell therapy presents its own distinct challenges, ranging from the choice of the iPS cell line to iPSC amplification, differentiation into target cells at a high degree of purity and at the required quality, amplification, formulation, filling and packaging of the final cell product, and cold chain logistics to the point of care, where national regulation needs to be observed regarding the preparation of the injectable dose and its administration to the patient. Various technologies reducing shear stress, robotics, automation, and integration are emerging to debottleneck capacity limitations, making the process consistent, and lowering cost of goods.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Kroll, M., & Kelly, K. (2026). Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions. Cell and Gene Therapy Insights, 12(3), 265–272. https://doi.org/10.18609/cgti.2026.034
MLA 9
Kroll, Mathias, and Kilian Kelly. “Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions.” Cell and Gene Therapy Insights, vol. 12, no. 3, 2026, pp. 265–272. https://doi.org/10.18609/cgti.2026.034.
Chicago
Kroll, Mathias and Kilian Kelly. 2026. “Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions.” Cell and Gene Therapy Insights 12 (3): 265–272. https://doi.org/10.18609/cgti.2026.034.
Harvard
Kroll, M. and Kelly, K. (2026) ‘Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions’, Cell and Gene Therapy Insights, 12(3), pp. 265–272. doi:10.18609/cgti.2026.034.
IEEE
M. Kroll and K. Kelly, “Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions,” Cell and Gene Therapy Insights, vol. 12, no. 3, pp. 265–272, 2026, doi: 10.18609/cgti.2026.034.
BibTeX
@article{kroll2026industrializing,
title = {{Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions}},
author = {Kroll, Mathias and Kelly, Kilian},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {3},
pages = {265–272},
doi = {10.18609/cgti.2026.034},
url = {https://doi.org/10.18609/cgti.2026.034}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- induced pluripotent stem cells
- allogeneic cell therapy
- cell therapy manufacturing
- iPSC differentiation
- cold chain
- cost of goods manufactured
- process automation
- robotics
Work with this paper
Most-cited papers in Biochemistry, Genetics and Molecular Biology
- PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENTOliver H. Lowry, NiraJ. Rosebrough, A. Lewis Farr and 1 more · Journal of Biological Chemistry · 1951 · 316,470 citations
- A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye BindingM Bradford · Analytical Biochemistry · 1976 · 256,780 citations
- Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT MethodKenneth J. Livak, Thomas D. Schmittgen · Methods · 2001 · 184,418 citations
- Molecular Cloning: A Laboratory ManualJoseph Sambrook, Elisabeth Fritsch, Tom Maniatis · UCLA - Biblioteca de Ciencias de la Salud · 1989 · 133,493 citations
- Basic Local Alignment Search ToolStephen F. Altschul, Warren R. Gish, Webb Miller and 2 more · Journal of Molecular Biology · 1990 · 100,529 citations
All highly cited Biochemistry, Genetics and Molecular Biology papers
Questions about this paper
How do I cite this paper in APA style?
Kroll, M., & Kelly, K. (2026). Industrializing allogeneic iPSC-derived cell therapies: challenges and solutions. Cell and Gene Therapy Insights, 12(3), 265–272. https://doi.org/10.18609/cgti.2026.034
How many times has this paper been cited?
0 times, according to OpenAlex on 21 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Cell and Gene Therapy Insights: sign in and open the full text from this page.
Who wrote this paper?
Mathias Kroll, Kilian Kelly.
What is the DOI of this paper?
10.18609/cgti.2026.034, permanently at https://doi.org/10.18609/cgti.2026.034. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 21 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.